Pre-exposure prophylaxis (PrEP) with antiretroviral medications is effective in preventing HIV infections. PrEP use has increased between 2013 and 2023. Multiple PrEP medications are available in ...

PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.

New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

In the last 30 years, HIV rates have gone down, in large part because of the game-changing prescription drug pre-exposure ...

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 ("I Am Study") at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and ...

How Was It Studied for the Prevention of HIV? Two large studies were conducted to see if Apretude is safe and effective as a PrEP regimen in people at risk of getting HIV. In both studies ...

Studies from OPERA and Trio cohorts provide further real-world evidence supporting CAB LA for PrEP’s high effectiveness and adherence in preventing HIV acquisition Patient-reported results for CAB LA ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

The AIDS Society of India (ASI) has called on the government to swiftly integrate HIV self-testing and pre-exposure ...

This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...